[关键词]
[摘要]
目的：评估曲安奈德(triamcinolone acetonide，TA)玻璃体腔和球后注射联合黄斑部格栅样光凝治疗糖尿病性黄斑水肿的临床疗效和安全性。
方法： 将52例62眼糖尿病性黄斑水肿患者随机分为璃体腔(0.1mL/4mg)注射TA组31眼和球后(1mL/40mg)注射TA组31眼，注药1mo后行黄斑部格栅样光凝，随访9mo观察视力、黄斑水肿情况及并发症。
结果： 两组患者治疗后1，3，6，9mo 4个随访时间点平均最佳矫正视力提高、黄斑水肿减轻，同治疗前比较均有统计学差异(P<0.05)，组间差异均无统计学意义(P>0.05)。球后注射组并发症低于玻璃体腔注射组，组间差异有统计学意义(P<0.05)。
结论： TA球后注射联合黄斑部格栅样光凝治疗糖尿病性黄斑水肿，同玻璃体腔注射的疗效无明显差异，且更安全。
[Key word]
[Abstract]
AIM: To evaluate the clinical effect and safety for diabetic macular edema(DME)with triamcinolone acetonide(TA)by intravitreous injection and retrobulbar injection combined with macular grid laser photocoagulation.
METHODS: Fifty-two patients(sixty-two eyes)with DME were randomly divided into two groups: thirty-one eyes were treated with an intravitreous injection of triamcinolone acetonide(IVTA)(0.1mL/4mg), and thirty- one eyes were treated with a retrobulbar injection of triamcinolone acetonide(RBTA)(1mL/40mg). Macular grid laser photocoagulation was used to treat all of the patients after one month. Follow-up 9mo, the change of macular edema and the incidence of complications were observed and measured.
RESULTS: For the different follow-up times at one month, three months, six months and nine months. Best corrected visual acuity(BCVA)and the change in macular edema of all patients improved after treatment. There were statistically differences between before treatment and after treatment in the change of BCVA and macular edema(P<0.05). But there was no statistically difference between the two groups(P>0.05). The difference in the incidence of complications between the two groups showed a statistically difference(P<0.05), RBTA group was safer.
CONCLUSION: RBTA combined with grid laser photocoagulation for DME has the same effect as IVTA, and it is safer.
[中图分类号]
[基金项目]
